Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder targeting the peripheral nervous system, causing muscle weakness and sensory issues. Often considered the chronic ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

A 60-year-old man regains mobility after advanced treatment. AGMC and GB Pant Hospital in Tripura mark a milestone in ...

Roivant Sciences Ltd.'s Vant model offers risk-isolated growth and monetization flexibility. Click for key ROIV drivers ...

Detailed price information for Dianthus Therapeutics Inc (DNTH-Q) from The Globe and Mail including charting and trades.

The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

Key Points GAAP EPS loss was $(0.88) for Q2 2025 GAAP revenue was $0.2 million for Q2 2025 Research and development expenses increased by 45.3%, while general and administrative expenses rose by 48.3% ...

Argenx has found a new doubles partner for its work to raise awareness of myasthenia gravis (MG). | Argenx has found a new doubles partner for its work to raise awareness of myasthenia gravis.

Baron Capital highlights biotech and robotic surgery as key growth drivers in Q2. See which stocks surged, which stumbled, and what it means for investors.

Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025All other ...